AHL
XENE icon

Abel Hall LLC’s Xenon Pharmaceuticals XENE Stock Holding History

Abel Hall LLC’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,757
Closed -$303K – 984
2025
Q4 		$303K Buy
+6,757
New +$284K 0.07% 331

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Abel Hall LLC's XENE Position: Q1 2026 in Review

Abel Hall LLC sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 6,757 shares — an estimated $303K sold.

Abel Hall LLC first reported a position in XENE in Q4 2025 and held it in 1 quarter. The position peaked at $303K in Q4 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Abel Hall LLC reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Abel Hall LLC sold 6,757 Xenon Pharmaceuticals shares in Q1 2026, an estimated $303K.
  • Abel Hall LLC first reported a position in Xenon Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Abel Hall LLC's Xenon Pharmaceuticals position peaked at $303K in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.